300937 Sichuan Hezong Medicine Easy-To-Buy PharmaceuticalWatchlist
About Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical Company
The company was founded in 2007 with a registered capital of 956.666.82 million yuan. It is headquartered in Liangli Medical and Health City, Chengdu, Sichuan Province. It is a comprehensive pharmaceutical distribution service provider focusing on the “out-of-hospital market”. The company has always focused on omni-channel pharmaceutical distribution services. Through innovative Internet and big data technology, efficient warehousing and logistics systems, perfect category management, and comprehensive and multi-level services, the company has built an SBBC industrial ecosystem, gradually reduced intermediate circulation links in the out-of-hospital market, and provided convenient, efficient, and low-cost pharmaceutical distribution services for the vast number of community medical terminals and primary medical institutions. Currently, the company operates more than 23,000 kinds of pharmaceutical products, covering Western medicine, proprietary Chinese medicines, Chinese herbal medicines, food and health food, medical devices and non-pharmaceuticals, etc., to fully meet the diverse needs of end customers in the out-of-hospital market. Corporate honors: In 2022, the company was selected as a national e-commerce model enterprise by the Ministry of Commerce of the People's Republic of China; the company was elected as the Secretary General Unit of the MAH Branch of the China Pharmaceutical Finance Association; the company was rated as “Sichuan New Format and New Model Innovative Enterprise” by the Sichuan Provincial Department of Commerce, Sichuan Development and Reform Commission, and the Sichuan Provincial Market Supervision Administration; the company was named “Top 100 Private Enterprises in Chengdu” and “Top 100 Service Enterprises in Chengdu” by the Pharmaceutical Business Branch of the Pharmaceutical Industry Chamber of Commerce of the China Federation of Industry and Commerce.
Tesco: Some amounts in the company's individual bank accounts have been frozen
GLONGHUI, September 14 | Tesco announced that recently, through bank inquiries, it was learned that the funds in the company's two bank accounts have been frozen. Up to now, the company has not received judicial documents such as court execution rulings. As of the disclosure date of the announcement, the actual amount frozen by the company was 58,194,688.48 yuan, accounting for 7.15% of the company's most recent audited net assets; the maximum amount frozen was 99,294,293.84 yuan, accounting for 12.20% of the company's most recent audited net assets.
The pharmaceutical commercial sector boosted the rise and suspension of Tesco
Gelonghui, August 23 | Tesco rose and stopped by 20cm. Chinese Health, Kaikai Industrial, First Pharmaceutical, Zhejiang Zhenyuan, and Shu Yu Civilian went up one after another.
SPD concept stock boosts Pharmaceutical Tesco by more than 10%
Gelonghui, August 23 | Tesco Pharmaceutical rose more than 10%, followed by Chinese Health, Kaikai Industrial, First Pharmaceutical, Zhejiang Zhenyuan, and Celi Medical.